Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study

被引：4

作者：

Kim, Ji Hoon ^{[1
]}

Nam, Hee-Chul ^{[1
]}

Kim, Chang-Wook ^{[1
]}

Cho, Hee Sun ^{[2
]}

Yoo, Jae-Sung ^{[2
]}

Han, Ji Won ^{[2
]}

Jang, Jeong Won ^{[2
]}

Choi, Jong Young ^{[2
]}

Yoon, Seung Kew ^{[2
]}

Yang, Hyun ^{[3
]}

Bae, Si Hyun ^{[3
]}

Kim, Suho ^{[4
]}

Oh, Jung Suk ^{[4
]}

Chun, Ho Jong ^{[4
]}

Jeon, Chang Ho ^{[5
]}

Ahn, Jaegyoon ^{[6
]}

Sung, Pil Soo ^{[1
]}

机构：

[1] Catholic Univ Korea, Uijeongbu St Marys Hosp, Coll Med, Dept Ophthalmol, Seoul 06591, South Korea

[2] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Radiol, Seoul 06591, South Korea

[3] Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Psychiat, Seoul 06591, South Korea

[4] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Radiol, Seoul 06591, South Korea

[5] Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Radiol, Seoul 06591, South Korea

[6] Incheon Natl Univ, Dept Comp Sci & Engn, Incheon 22573, South Korea

来源：

CANCERS | 2023年 / 15卷 / 17期

关键词：

atezolizumab plus bevacizumab; hepatic artery infusion chemotherapy; hepatocellular carcinoma; overall survival; progression-free survival; CLINICAL-PRACTICE; SAFETY;

D O I：

10.3390/cancers15174233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study aimed to compare the prognosis and characteristics of patients with advanced hepatocellular carcinoma treated with first-line atezolizumab plus bevacizumab (AB) combination therapy and hepatic artery infusion chemotherapy (HAIC). We retrospectively assessed 193 and 114 patients treated with HAIC and AB combination therapy, respectively, between January 2018 and May 2023. The progression-free survival (PFS) of patients treated with AB combination therapy was significantly superior to that of patients treated with HAIC (p < 0.05), but there was no significant difference in overall survival (OS). After propensity score matching, our data revealed no significant differences in OS and PFS between patients who received AB combination therapy and those who received HAIC therapy (p = 0.5617 and 0.3522, respectively). In conclusion, our propensity score study reveals no significant differences in OS and PFS between patients treated with AB combination therapy and those treated with HAIC.

引用

页数：12

共 37 条

[1] Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Ahn, Young Eun
Suh, Sang Jun
Yim, Hyung Joon
Seo, Yeon Seok
Yoon, Eileen L.
Kim, Tae Hyung
Lee, Young Sun
Yim, Sun Young
Kim, Hae Rim
Kang, Seong Hee
Jung, Young Kul
Kim, Ji Hoon
Yeon, Jong Eun
Um, Soon Ho
Byun, Kwan Soo
[J]. GUT AND LIVER, 2021, 15 (02) : 284 - 294
[2] Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
Casadei-Gardini, Andrea
Rimini, Margherita
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Rimassa, Lorenza
Presa, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Tovoli, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Pressiani, Tiziana
Montes, Margarida
Vivaldi, Caterina
Solda, Caterina
Piscaglia, Fabio
Hiraoka, Atsushi
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Iavarone, Massimo
Di Costanzo, Giovanni
Marra, Fabio
Scartozzi, Mario
Tamburini, Emiliano
Cabibbo, Giuseppe
Foschi, Francesco Giuseppe
Silletta, Marianna
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
[J]. EUROPEAN JOURNAL OF CANCER, 2023, 180 : 9 - 20
[3] Casadei-Gardini A, 2022, J CLIN ONCOL, V40
[4] Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
Chen, Ching-Tso
Liu, Tsung-Hao
Shao, Yu-Yun
Liu, Kao-Lang
Liang, Po-Chin
Lin, Zhong-Zhe
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
[5] Cheng AL, 2022, J HEPATOL, V76, P862, DOI [10.1016/j.jhep.2021.11.030, 10.1016/j.jceh.2022.07.003]
[6] Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
Cheon, Jaekyung
Yoo, Changhoon
Hong, Jung Yong
Kim, Han Sang
Lee, Dae-Won
Lee, Myung Ah
Kim, Jin Won
Kim, Ilhwan
Oh, Sang-Bo
Hwang, Jun-Eul
Chon, Hong Jae
Lim, Ho Yeong
[J]. LIVER INTERNATIONAL, 2022, 42 (03) : 674 - 681
[7] Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis
Choi, Jong Hwan
Chung, Woo Jin
Bae, Si Hyun
Song, Do Seon
Song, Myeong Jun
Kim, Young Seok
Yim, Hyung Joon
Jung, Young Kul
Suh, Sang Jun
Park, Jun Yong
Kim, Do Young
Kim, Seung Up
Cho, Sung Bum
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) : 469 - 478
[8] Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
D'Alessio, Antonio
Fulgenzi, Claudia Angela Maria
Nishida, Naoshi
Schoenlein, Martin
von Felden, Johann
Schulze, Kornelius
Wege, Henning
Gaillard, Vincent E.
Saeed, Anwaar
Wietharn, Brooke
Hildebrand, Hannah
Wu, Linda
Ang, Celina
Marron, Thomas U.
Weinmann, Arndt
Galle, Peter R.
Bettinger, Dominik
Bengsch, Bertram
Vogel, Arndt
Balcar, Lorenz
Scheiner, Bernhard
Lee, Pei-Chang
Huang, Yi-Hsiang
Amara, Suneetha
Muzaffar, Mahvish
Naqash, Abdul Rafeh
Cammarota, Antonella
Personeni, Nicola
Pressiani, Tiziana
Sharma, Rohini
Pinter, Matthias
Cortellini, Alessio
Kudo, Masatoshi
Rimassa, Lorenza
Pinato, David J.
[J]. HEPATOLOGY, 2022, 76 (04) : 1000 - 1012
[9] Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis
D'Alessio, Antonio
Weinmann, Arndt
Galle, Peter R.
Fulgenzi, Claudia Angela Maria
Bettinger, Dominik
Bengsch, Bertram
Vogel, Arndt
Balcar, Lorenz
Scheiner, Bernhard
Navaid, Musharraf
Naqash, Abdul Rafeh
Personeni, Nicola
Pressiani, Tiziana
Sharma, Rohini
Pinter, Matthias
Cortellini, Alessio
Rimassa, Lorenza
Pinato, David James
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[10] Daher Darine, 2023, J Liver Cancer, V23, P127, DOI 10.17998/jlc.2022.12.30

← 1 2 3 4 →